TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29205286
Drug: Anamorelin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anamorelin (100 mg daily for 12 weeks)
Study: 27127006
Drug: Avastin (bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin (bevacizumab) in combination with Temozolomide (TMZ) and Radiotherapy
Study: 23647914
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily life)
Study: 18470902
Drug: Cladribine and
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine and cyclophosphamide combination
Study: 18470902
Drug: Cyclophosphamide, vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, vincristine, and prednisone combination
Study: 18470902
Drug: Cladribine-containing regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine-containing regimens (both cladribine alone and cladribine and cyclophosphamide combination)
Study: 18470902
Drug: Cladribine alone
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine alone and cladribine and cyclophosphamide combination
Study: 18470902
Drug: Cladribine alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine alone, cladribine and cyclophosphamide combination, and cyclophosphamide, vincristine, and prednisone combination
Study: 11012559
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg at 40 degrees C
Study: 11012559
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg at 22 degrees C
Study: 1577361
Drug: Individually matched
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually matched haloperidol dosage for 14 days
Study: 1577361
Drug: Fixed doses
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed doses (10 mg and 20 mg haloperidol)
Study: 3883868
Drug: Full-dose total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose total lymphoid irradiation (2000 rad)
Study: 3883868
Drug: Low-dose total
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose total lymphoid irradiation (200 rad)
Study: 26402923
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg testosterone
Study: 24363302
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite 40 mg
Study: 24363302
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite 80 mg
Study: 16208798
Drug: Oral‐B 3D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B 3D Excel (3DE)
Study: 12504934
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 300 microg of Rhophylac
Study: 12504934
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 300 microg of Rhophylac
Study: 10900538
Drug: Paracetamol generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol generic products (500 mg tablets)
Study: 1516462
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg b.i.d.
Study: 1516462
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 20 mg/kg b.i.d.
Study: 1516462
Drug: Cefaclor 10
Normalized name: cefaclor 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 10 mg/kg t.i.d.
Study: 6373153
Drug: Microcrystalline hydroxyapatite
Normalized name: Microcrystalline Hydroxyapatite Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline hydroxyapatite compound (MCHC) 6 to 8 g for 12 months
Study: 24727160
Drug: Once-weekly 56.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 56.5 μg teriparatide for 72 weeks
Study: 3554627
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal suspension (105 g)
Study: 3554627
Drug: Sorbitol-charcoal suspension
Normalized name: activated charcoal / sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol-charcoal suspension (105 g)
Study: 23910201
Drug: Loaded miniscrew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loaded miniscrew implants
Study: 23910201
Drug: Unloaded miniscrew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded miniscrew implants
Study: 14505201
Drug: Ruby laser
Normalized name: Ruby arsenic
DrugBank: Tetraarsenic tetrasulfide (DB19141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruby laser treatment (3 treatments given at monthly intervals)
Study: 10872958
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment (8.5% sustained-release biodegradable gel)
Study: 10872958
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction/reinforcement (Control)
Study: 9331117
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 plus carboplatin (AUC 6)
Study: 7963760
Drug: Localized radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized radiation treatment (1.8 Gy per fraction, 17 fractions)
Study: 7963760
Drug: Localized radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized radiation treatment
Study: 30449208
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogen (CEE) and 100 mg of micronized progesterone (MP)
Study: 30449208
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of CEE and 100 mg of MP
Study: 30449208
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of CEE and 10 mg of dydrogesterone (DDG)
Study: 16512751
Drug: 0.2% alcohol-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% alcohol-free chlorhexidine mouthrinse used twice per day for 1 week
Study: 16512751
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse used twice per day for 1 week
Study: 8984313
Drug: Early ultrasound-guided
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ultrasound-guided compression therapy for pseudoaneurysms, duration not specified.
Study: 1856917
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of local anesthetics (25 mg lidocaine and 25 mg prilocaine per gm)
Study: 6349654
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (300 mg per day for one week)
Study: 6349654
Drug: Oxyphenbutazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyphenbutazone (600 mg per day)
Study: 31711451
Drug: ROP1.3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROP1.3 group (1.3 mL/kg of 0.15% ropivacaine)
Study: 31711451
Drug: ROP1.0 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROP1.0 group (1.0 mL/kg of 0.15% ropivacaine)
Study: 28957818
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg epilutein and 2 mg lutein (group 1)
Study: 28957818
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein (group 2)
Study: 24133005
Drug: OTG3% 84
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTG3% 84 mg/day
Study: 18645727
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (4 ml equal to 40 mg in 10 min)
Study: 18645727
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml of 0.9% saline solution)
Study: 16842467
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg, rifabutin 150 mg and amoxicillin 1 g, each given b.d. for 7 days (ERA)
Study: 16842467
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg and amoxicillin 1000 mg, each given t.d.s. for 14 days (OA)
Study: 1641524
Drug: Oestriol 3
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol 3 mg p.o. per day for 4 weeks, followed by 1 mg per day for 8 weeks
Study: 6361789
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg plus codeine 60 mg
Study: 30763195
Drug: Decolonization (chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decolonization (chlorhexidine mouthwash, baths or showers with chlorhexidine, and nasal mupirocin for 5 days twice per month for 6 months)
Study: 27184521
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review + social interaction
Study: 27184521
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review + exercise
Study: 27184521
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review alone
Study: 24840143
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EG) received weekly patient progress feedback (OQ-45) and clinical support tools (CST) starting at t2.
Study: 24840143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) received treatment-as-usual without additional feedback or tools.
Study: 9415087
Drug: Computer-assisted learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted learning (CAL) programs in addition to daily formal teaching
Study: 9415087
Drug: Daily formal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily formal teaching only (Control)
Study: 29696919
Drug: Low-frequency electrical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electrical therapy combined with rehabilitation training
Study: 25988390
Drug: Ultrasound-guided SIJ
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided SIJ injection
Study: 25988390
Drug: Fluoroscopy-guided SIJ
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided SIJ injection
Study: 16874169
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (not received)
Study: 14571103
Drug: L-Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (2 g twice a day)
Study: 3555129
Drug: 10 hours
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 hours of daily continuous passive motion (CPM) starting on the 2nd postoperative day
Study: 19487625
Drug: Antipsychotics (clozapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (clozapine, risperidone, or olanzapine)
Study: 19487625
Drug: Pramipexole (a
Normalized name: Pramipexole (as pramipexole dihydrochloride) 1.05 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (a D(3) receptor-preferring agonist)
Study: 15531659
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus antioxidants (2.7 g EPA and DHA/d)
Study: 11417430
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 19‐nor‐4‐androstene‐3,17‐dione and 56 mg of 19‐nor‐4‐androstene‐3,17‐diol (156 mg total norsteroid per day)
Study: 9893540
Drug: fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 micrograms.kg-1 + ketamine 0.25 mg.kg-1
Study: 8031484
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B P-35)
Study: 7972859
Drug: High-potency neuroleptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency neuroleptics treatment for 3 weeks
Study: 7972859
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no neuroleptic treatment)
Study: 25426617
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg on day 1 for one 3-week cycle)
Study: 25426617
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab and Everolimus
Study: 17394699
Drug: Finasteride (5alpha-reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5alpha-reductase inhibitor)
Study: 15952679
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion in combination with canal injection for local anaesthesia with Mepivacaine 2% and Adrenalin 1/100,000
Study: 12364308
Drug: Changes to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes to the order of presenting treatments, improved presentation of information, and redefinition of the non-radical arm.
Study: 9667262
Drug: Pegylated-liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated-liposomal doxorubicin (20 mg/m2)
Study: 9667262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxorubicin (20 mg/m2), bleomycin (10 mg/m2), and vincristine (1 mg) (ABV)
Study: 8110579
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg or 30 mg i.m., 6 hourly
Study: 2530869
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amlodipine administered intravenously
Study: 28392080
Drug: High-dose loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose loop diuretic strategy (HDLD-strategy)
Study: 21994424
Drug: MK-0941 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 10 mg
Study: 21994424
Drug: MK-0941 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 20 mg
Study: 21994424
Drug: MK-0941 30
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 30 mg
Study: 21994424
Drug: MK-0941 40
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 40 mg
Study: 21994424
Drug: MK-0941 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 (all doses)
Study: 12492802
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micro g kg‐1
Study: 12492802
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micro g kg‐1 plus dexamethasone 8 mg
Study: 9712230
Drug: Fenfluramine 60
Normalized name: fenfluramine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine 60 mg orally
Study: 30006653
Drug: Nasal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal lavage with saline solution at room temperature (20 °C)
Study: 30006653
Drug: Nasal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal lavage with saline solution at body temperature (37 °C)
Study: 22023518
Drug: Rituximab-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab-containing therapy before transformation
Study: 22023518
Drug: Rituximab-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab-containing therapy after transformation
Study: 18766955
Drug: Spironolactone 2
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 2 mg/kg/day for 12 weeks
Study: 17979861
Drug: Hand-arm bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-arm bimanual intensive therapy (HABIT); 6 hours per day for 10 days.
Study: 17979861
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group; no specific intervention mentioned.
Study: 8848903
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg (n = 18)
Study: 26509605
Drug: 24-week peginterferon/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week peginterferon/ribavirin treatment
Study: 26509605
Drug: 48-week peginterferon/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-week peginterferon/ribavirin treatment
Study: 21083855
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg per day) for 4 weeks
Study: 19299805
Drug: NS1209 (322
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS1209 (322 mg)
Study: 11137181
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 mcg/daily)
Study: 6342836
Drug: Timolol maleate,
Normalized name: Timolol Maleate, Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol maleate, 10 mg twice daily
Study: 27710972
Drug: Stopped gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped gefitinib treatment upon disease progression (n = 35)
Study: 18424480
Drug: Interferon-beta therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta therapy
Study: 12519430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard chemotherapy without specified filgrastim dose)
Study: 9058693
Drug: Nebulized ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ouabain (1 mg)
Study: 7939931
Drug: Iron tablet
Normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablet 1 (60 mg elemental iron)
Study: 7939931
Drug: Iron tablet
Normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablet 2 (60 mg elemental iron)
Study: 7939931
Drug: Aqueous Fe(II)-sulphate
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous Fe(II)-sulphate solution (120 mg elemental iron)
Study: 3510524
Drug: Nicardipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (90 mg/day in 3 divided doses)
Study: 3510524
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg/day in 3 divided doses)
Study: 21982342
Drug: L-BLP25 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BLP25 plus best supportive care (BSC)
Study: 12431827
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin at an area under the curve of 5 mg/ml/min on day 1
Study: 12431827
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 1 every 21 days
Study: 28872480
Drug: Norepinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (10 µg)
Study: 28872480
Drug: Phenylephrine (137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (137 µg)
Study: 28872480
Drug: Norepinephrine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (8 µg)
Study: 23266540
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) administered at bedtime
Study: 23266540
Drug: Captopril (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (not specified dosage)
Study: 19361598
Drug: Aspirin (≤325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (≤325 mg/day)
Study: 19361598
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (ER-DP)
Study: 19361598
Drug: Anticoagulation (warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation (warfarin and other vitamin K antagonists)
Study: 17018383
Drug: Deferasirox 10
Normalized name: Deferasirox 100 mg dispersible oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox 10 mg/kg/day (modified after 12 weeks)
Study: 17018383
Drug: Deferasirox 10
Normalized name: Deferasirox 100 mg dispersible oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox 10 mg/kg/day (mean dose 11.3 mg/kg/day)
Study: 17018383
Drug: Deferasirox (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (once-daily dosing)
Study: 15466880
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg at baseline, 30 mg at months 1, 2, 3, and 6)
Study: 10906163
Drug: ABT-627 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-627 (20 mg)
Study: 10906163
Drug: ABT-627 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-627 (5 mg)
Study: 3252453
Drug: CW dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: CW dye laser treatment
Study: 3252453
Drug: CW argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: CW argon laser treatment
Study: 29486720
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (200 μg)
Study: 27914744
Drug: Vaccine-naïve controls
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-naïve controls